University of Michigan
A Patient-Facing Tool to Reduce Opioid, Psychotropic Polypharmacy in People Living With Dementia
Health Care Systems
• University of Michigan – Department of Internal Medicine
• Henry Ford Health System
Dr. Maust is an associate professor of psychiatry at the University of Michigan Medical School and research scientist with the Center for Clinical Management Research of the VA Ann Arbor Healthcare System. Dr. Maust is a board-certified geriatric psychiatrist and health services researcher. His research focuses on understanding determinants and outcomes of potentially inappropriate psychotropic prescribing to older adults, with particular interest in benzodiazepines, antipsychotics, and psychotropic/opioid polypharmacy in both the outpatient and long-term care settings. His other area of interest is in understanding how caregivers of people living with dementia shape how the person with dementia interacts with the health care system. Dr. Maust earned his medical degree from Johns Hopkins University and completed his training in psychiatry and geriatric psychiatry at the University of Pennsylvania.
RATIONALE: Central nervous system-active polypharmacy (CNS polyRx; i.e., overlapping prescriptions of ≥3 psychotropic and opioid medications) is common among people living with dementia (PLWD) even though the evidence base to support use of even single agents in this population is limited. Direct-to-patient education (e.g., EMPOWER) has demonstrated efficacy to prompt deprescribing among older adults but has not focused on PLWD and their care partners previously.
OBJECTIVE: To adapt direct-to-patient education to use with PLWD and engaged care partners and specifically address CNS polyRx; pilot the feasibility of using the electronic health record to identify PLWD experiencing CNS polyRx with engaged care partners and then implement the direct-to-dyad education; and ascertain any prescribing changes in the electronic health record.
SETTING: Four primary care clinics at the University of Michigan Health and Henry Ford Health systems.
POPULATION: Primary care patients living with dementia experiencing CNS polyRx with engaged care partners.
INTERVENTION: A direct-to-dyad educational tool sent by mail that presents potential risks of the currently prescribed regimen, with the goal of prompting a conversation with their pharmacist or prescribing clinician.
OUTCOMES: The primary clinical outcome is a change in the burden of CNS-active prescriptions. Implementation endpoints include: establishing enrollment feasibility (i.e., PLWD experience CNS polyRx for whom we can also identify a care partner) and implementation feasibility (i.e., documented evidence of discussion with a clinician about these medications after the tool is sent to those eligible).
IMPACT: If successful, this pilot study will establish the feasibility of a large-scale embedded pragmatic clinical trial to test this type of direct-to-dyad education to address potentially inappropriate prescribing. Given the potential harms and related costs associated with CNS polyRx, this low-touch intervention could have significant impact even if the effect is relatively small.